Keyphrases
Gefitinib
100%
Whole Population
100%
Pharmacogenetic Research
100%
Mutation-negative
100%
I-PASS
100%
Adaptive Clinical Trial Design
100%
Simulation-based
100%
Interim Analysis
66%
Effect Estimates
66%
Response Rate
66%
Treatment Effect
66%
EGFR mutation
66%
Adaptive Trial
66%
Simulation Model
33%
Patient Demographics
33%
Potential Gains
33%
Phase II Trial
33%
Subgroup Analysis
33%
Population Enrichment
33%
Adaptive Trial Design
33%
Conditional Power
33%
Small Clinical Trials
33%
Tumor Response
33%
Non-small Cell Lung Cancer Patients
33%
Number of Patients
33%
Medicine and Dentistry
Pharmacogenetics
100%
Gefitinib
100%
Clinical Trial Design
100%
Adaptive Clinical Trial
100%
Epidermal Growth Factor Receptor
66%
Interim Analysis
66%
Treatment Effect
66%
Patient Population
33%
Neoplasm
33%
Subgroup Analysis
33%
Non Small Cell Lung Cancer
33%
Phase III Trials
33%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacogenetics
100%
Clinical Trial Design
100%
Gefitinib
100%
Adaptive Clinical Trial
100%
Epidermal Growth Factor Receptor
66%
Non Small Cell Lung Cancer
33%
Neoplasm
33%
Phase III Trials
33%
Nursing and Health Professions
Gefitinib
100%
Epidermal Growth Factor Receptor
66%
Patient Population
33%
Neoplasm
33%
Non Small Cell Lung Cancer
33%